Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: Possible antioxidant mechanisms

British Journal of Pharmacology

Volumn 136, Issue 2, 2002, Pages 193-200

  Naidu, Pattipati S ^a   Singh, Amanpreet ^a   Kulkarni, Shrinivas K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

carvedilol; neuroleptics; Oxidative stress; tardive dyskinesia; VCMs

Indexed keywords

CARVEDILOL; CATALASE; CHLORPROMAZINE; CLOZAPINE; GLUTATHIONE; HALOPERIDOL; NEUROLEPTIC AGENT; SUPEROXIDE DISMUTASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ASSAY; FOREBRAIN; LIPID PEROXIDATION; MALE; MASTICATION; NONHUMAN; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; TARDIVE DYSKINESIA;

EID: 0036273891     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704717     Document Type: Article

References (57)

1. Effects of carvedilol and its analog BM-910228 on Mitochondrial function and oxidative stress
2. Neurotoxicity associated with neuroleptic induced oral dyskinesias in rats implications for tardive dyskinesia?
3. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: Comparison with atypical antipsychotics
4. Neuroleptic medications inhibit complex I of the electron transport chain
5. Free radicals and tardive dyskinesia
6. Tardive dyskinesia and schizophrenic burnout: The possible involvement of cytotoxic free radicals
7. Tardive dyskinesia: Pathophysiology and animal models
8. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population
9. Hydrogen production in neurones: Implications for understanding Parkinson's disease
10. In vivo effects of psychotropic agents on the physical properties of cell membranes in the rat brain
11. Oxidative stress glutamate and neurodegenerative disorders
12. Dopamine receptor binding and pharmacological potencies and antischizophrenic drugs
13. Treatment of tardive dyskinesia
14. Tardive dyskinesia: Possible involvement of free radical and treatment with vitamin E
15. Tissue sulfhydryl groups
16. Formation of pyridinium species of haloperidol in human liver and brain
17. Carvedilol update IV: Prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure
18. Carvedilol: A novel multiple action antihypertensive drug that provides major organ protection
19. Neurobiological substrates of tardive dyskinesia: The GABA hypothesis
20. Oxygen radicals diminish dopamine transporter function in rat striatum
21. Haloperidol-induced neurotoxicity - Possible implications for tardive dyskinesia
22. On the metabolism of haloperidol
23. Extrapyramidal symptoms in neuroleptic recipients
24. Tardive dyskinesia: Review of treatments past, present, and future
25. Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrohydropyridine analogue of haloperidol
26. Generation of superoxide radical during autooxidation of hydroxylamine and an assay for superoxide dismutase
27. Tardive dyskinesia: An update
28. Protein measurement with the Folin-Phenol reagent
29. Catalase
30. Carvedilol: A novel multiple action antihypertensive drug
31. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia
32. A comparison of carvedilol and metoprolol antioxidant activities in vitro
33. Carvedilol, a new beta adrenoceptor blocker and free radical scavenger, attenuates myocardial ischemia reperfusion injury in hypercholesterolemic rabbits
34. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): Possible involvement of calcium and nitric oxide
35. Effect of 5-HT1A and 5-HT2A/2C receptor modulations on neuroleptic-induced vacuous chewing movements
36. Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats
37. In vitro pharmacological profile of the novel β-adrenoceptor antagonist and vasodilator carvedilol
38. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats
39. Antioxidant action of the antihypertensive drug carvedilol, against lipid peroxidation
40. Carvedilol: An effective antihypertensive drug with antiischemic/antioxidant cardioprotective properties
41. Glutathione depletion and formation of glutathione protein mixed disulfide following exposure of brain mitochondria to oxidative stress
42. The prevalence of tardive dyskinesia in a mentally retarded population
43. The Pharmacology of carvedilol
44. Induction of reactive oxygen species in neurones by haloperidol
45. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats
46. Oxidative stress and thiol modification induced by chronic administration of haloperidol
47. Vitamin E for neuroleptic-induced tardive dyskinesia
48. Carvedilol inhbition of lipid peroxidation. A new antioxidative metabolism
49. Haloperidol-induced changes in glutathione and energy metabolism effect of nicergolin
50. Regional brain manganese levels in animal model of tardive dyskinesia
51. Mechanism of lipid peroxide formation in animal tissues
52. Effects of haloperidol metabolites on neurotransmitter uptake and release: Possible role of neurotoxicity and tardive dyskinesia
53. Anti-NO action of carvedilol in cell-free system and in vascular endothelial cells
54. Carvedilol, a new vasodilator and β-adrenergic blocking agents adrenoceptor antagonist, is an antioxidant and free radical scavenger
55. Carvedilol, a new vasodilator and β-adrenoreceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes
56. Carvedilol, a new β-adrenoreceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils
57. Carvedilol, a new vasodilating β-adrenergic blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth cells